Cross-modulatory effects of clopidogrel and heparin on platelet and fibrin incorporation in thrombosis

Blood Coagulation and Fibrinolysis

Volumn 24, Issue 6, 2013, Pages 593-598

  Cooley, Brian C ^a   Herrera, Anthony J ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

anticoagulation; arterial thrombosis; mouse models; platelet inhibition; venous thrombosis

Indexed keywords

CLOPIDOGREL; FIBRIN; HEPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; FIBRIN FORMATION; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; VEIN THROMBOSIS;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; FIBRIN; HEPARIN; MALE; MICE; MICE, INBRED C57BL; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; VENOUS THROMBOSIS;

EID: 84882454490     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3283602a03     Document Type: Article

References (42)

1. Geerts WH, Bergqvist D, Pineo GF, Samama CM, Lassen MR, Colwell CW. American College of Chest Physicians: Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133 (Suppl 6): 381S-453S.
2. Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ, et al. American College of Chest Physicians: Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest 2008; 133:670S-707S.
3. Marsh JD, Keyrouz SG. Stroke prevention and treatment. J Am Coll Cardiol 2010; 56:683-691.
4. Turpie AGG, Esmon C. Venous and arterial thrombosis-pathogenesis and the rationale for anticoagulation. Thromb Haemost 2011; 105:586-596.
5. Lijfering WM, Flinterman LE, Vandenbroucke JP, Rosendaal FR, Cannegieter SC. Relationship between venous and arterial thrombosis: a review of the literature from a causal perspective. Sem Thromb Haemostas 2011; 37:885-896.
6. Cooley BC. In vivo fluorescence imaging of large-vessel thrombosis in mice. Arterioscler Thromb Vasc Biol 2011; 31:1351-1356.
7. Hui KY, Haber E, Matsueda GR. Monoclonal antibodies to a synthetic fibrinlike peptide bind to human fibrin but not fibrinogen. Science 1983; 222:1129-1131.
8. Bucx JJ, de Scheerder I, Beatt K, van den Brand M, Suryapranata H, de Feyter PJ, et al. The importance of adequate anticoagulation to prevent early thrombosis after stenting of stenosed venous bypass grafts. Am Heart J 1991; 121:1389-1396.
9. Clagett GP, Sobel M, Jackson MR, Lip GY, Tangelder M, Verhaeghe R. Antithrombotic therapy in peripheral arterial occlusive disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl 3):609S-626S.
10. Imperiale TF, Speroff T. A meta-analysis of methods to prevent venous thromboembolism following total hip replacement. JAMA 1994; 271:1780-1785.
11. Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006; 452:175-180.
12. Dorr LD, Gendelman V, Maheshwari AV, Boutary M, Wan Z, Long WT. Multimodel thromboprophylaxis for total hip and knee arthroplasty based on risk assessment. J Bone Joint Surg Am 2007; 89:2648-2657.
13. Gilbert GE, Arena AA. Activation of the factor VIIIa-factor IXa enzyme complex of blood coagulation by membranes containing phosphatidyl-L-serine. J Biol Chem 1996; 271:11120-11125.
14. Leung R,Gwozdz AM, Wang H, Bang KW, Packham MA, Freedman J, et al. Persistence of procoagulant surface expression on activated human platelets: involvement of apoptosis and aminophospholipid translocase activyt. J Thromb Haemost 2007; 5:560-570.
15. Keuren JF, Wielders SJ, Willems GM, Morra M, Lindhout T. Fibrinogen adsorption, platelet adhesion and thrombin generation at heparinized surfaces exposed to flowing blood. Thromb Haemost 2002; 87:742-747.
16. Jirouskova M, Dyr JE, Suttnar J, Holada K, Trnkova B. Platelet adhesion to fibrinogen, fibrin monomer, and fibrin protofibrils in flowing blood-the effect of fibrinogen immobilization and fibrin formation. Thromb Haemost 1997; 78:1125-1131.
17. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu MY, Smith PL, et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J Thromb Haemostas 2005; 3:695-702.
18. Wang X, Smith PL, Hsu MY, Ogletree ML, Schumacher WA. Murine model of ferric chloride-induced vena cava thrombosis: evidence for effect of potato carboxypeptidase inhibitor. J Thromb Haemostas 2006; 4:403-410.
19. Wang X, Smith PL, Hsu MY, Gailani D, Schumacher WA, Ogletree ML, et al. Effects of factor XI deficiency on ferric chloride-induced vena cava thrombosis in mice. J Thromb Haemostas 2006; 4:1982-1988.
20. Eslin DE, Zhang C, Samuels KJ, Rauova L, Zhai L, Niewlarowski S, et al. Transgenic mice studies demonstrate a role for platelet factor in thrombosis: dissociation between anticoagulant and antithrombotic effect of heparin. Blood 2004; 104:3173-3180.
21. Sorg H, Hoffmann JN, Menger MD, Lindenblatt N, Goehring P, Vollmar B. Antithrombin is as effective as heparin and hirudin to prevent formation of microvascular thrombosis in a murine model. Thromb Haemostas 2006; 96:371-377.
22. Mills DC, Puri R, Hu CJ, Minniti C, Grana G, Freedman MD, et al. Clopidogrel inhibits the binding of ADP analogues to the receptor mediating inhibition of platelet adenylate cyclase. Arterioscler Thromb 1992; 12:430-436.
23. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CuURE study. Lancet 2001; 358:527-533.
24. Investigators MSR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010; 363:930-942.
25. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, et al. GRAVITAS Investigators: standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011; 305:1097-1105.
26. Kawasaki T, Taniguchi M, Moritani Y, Uemure T, Shigenaga T, Takamatsu H, et al. Pharmacoloical properties of YM-254890, a specific G(alpha)q/inhibitor, on thrombosis and neointima formation in mice. Thromb Haemostas 2005; 94:184-192.
27. Cornelissen I, Palmer D, David T, Wilsbacher L, Concengco C, Conley P, et al. Roles and interactions among protease-activated receptors and P2ry12 in hemostasis and thrombosis. Proc Natl Acad Sci USA 2010; 107:18605-18610.
28. Eckly A, Hechler B, Freund M, Zerr M, Cazenave JP, Lanza F, et al. Mechanisms underlying FeCl3-induced arterial thrombosis. J Thromb Haemostas 2011; 9:779-789.
29. Sturgeon SA, Jones C, Angus JA, Wright CE. Adaptation of the Folts and electrolytic methods of arterial thrombosis for the study of antithrombotic molecules in small animals. J Pharmacol Toxicol Meth 2006; 53:20-29.
30. Lorrain J, Lechaire I, Gauffeny C, Masson R, Roame N, Herault JP, et al. Effects of SanOrg123781A, a synthetic hexadecasaccharide, in a mouse model of electrically induced carotid artery injury: synergism with the antiplatelet agent clopidogrel. J Pharmacol Exp Therapeut 2004; 309:235-240.
31. Schulz C, Konrad I, Sauer S, Orschiedt L, Koellnberger M, Lorenz R, et al. Effect of chronic treatment with acetylsalicylic acid and clopidogrel on atheroprogression and atherothrombosis in ApoE-deficient mice in vivo. Thromb Haemostas 2008; 99:190-195.
32. Lenain N, Freund M, Leon C, Cazenave JP, Gachet C. Inhibition of localized thrombosis in P2Y1-deficient mice and rodents treated with MRS2179, a P2Y1 receptor antagonist. J THromb Haemostas 2003; 1:1144-1149.
33. Hechler B, Nonne C, Roh EJ, Cattaneo M, Cazenave JP, Lanza F, et al. MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate] , a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J Pharmacol Exp Therapeut 2006; 316:556-563.
34. Hu L, Fan Z, Du H, Ni R, Zhang S, Yin K, et al. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb Haemost 2011; 106:1203-1214.
35. Gould WR, Baxi SM, Schroeder R, Peng YW, Leadley RJ, Peterson JT, et al. Gas6 receptors Axl, Sky and Mer enhance platelet activation and regulate thrombotic response. J Thromb Haemost 2005; 3:733-741.
36. Wang X, Xu L. An optimized murine model of ferric chloride-induced arterial thrombosis for thrombosis research. Thrombos Res 2005; 115:95-100.
37. von Bruhl ML, Stark K, Steinhart A, Chandraratne S, Konrad I, Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J Exp Med 2012; 209:819-835.
38. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of postoperative deep-vein thrombosis. Lancet 1969; 2:230-232.
39. Flanc C, Kakkar VV, Clarke MB. The detection of venous thrombosis of the legs using 125-I-labelled fibrinogen. Br J Surg 1968; 55:742-747.
40. Maynard MJ, Sculco TP, Ghelman B. Progression and regression of deep vein thrombosis after total knee arthroplasty. Clin Orthop Related Res 1991; 273:125-130.
41. Cooley BC, Szema L, Chen CY, Schwab JP, Schmeling G. A murine model of deep vein thrombosis: characterization and validation in transgenic mice. Thromb and Haemostas 2005; 94:498-503.
42. Cooley BC, Chen CY, Hess R, Schmeling G. Incomplete resolution of deep vein thrombosis under reduced flow conditions. Thrombos Res 2013; 131:55-58.